annb0t
Top 20
Compete data from global Phase III ZIRCON study of Telix's investigational imaging agent TLX250-CDx in clear cell renal cell carcinoma (ccRCC) will be presented at American Society of Clinical Oncology (ASCO) Genitourinary (GU) Cancers Symposium (ASCO GU) in February 2023 Telix pipeline featured across seven presentations including first reveal of the STARBURST study exploring utility of TLX250-CDx in tumour types beyond ccRCC; TLX250 therapy in ccRCC; and real-world experience using 68Ga-PSMA-1...
>>> Read more: ZIRCON Phase III Renal Cancer Study to be Presented at ASCO GU along with Theranostic Pipeline Advances
>>> Read more: ZIRCON Phase III Renal Cancer Study to be Presented at ASCO GU along with Theranostic Pipeline Advances
